 II. Patients without actionable gene alteration or mutations in tissue at screening phase III. Patients who cannot tolerate anti-cancer therapy for at least 2 months should be withdrawn IV. Patients who cannot cooperate the imaging study for response evaluation of anti-cancer therapy V. Patients tissue is too small to retrieve for NGS analysis. VI. Difficult blood sampling. VII. Clinicians judgement. 